XEN1101 is an investigational medicine being developed by Xenon Pharmaceuticals for the potential treatment of epilepsy and other indications, such as MDD.
Yes. XEN1101 has been evaluated in three Phase 1 studies in healthy volunteers and one Phase 2 study in epilepsy patients.
You will be assigned by chance to receive either the study drug or a placebo. You have a 2 in 3 chance (66.6%) of receiving the study drug.
A placebo is a pill or capsule that has no effect when taken and is used as a control in testing new drugs.
Investigational means the medicine is not approved by regulatory authorities like the US Food and Drug Administration (FDA), and it can only be used in clinical research studies like the X-NOVA study.